Stock CONTEXT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Context Therapeutics Inc.

Equities

US21077P1084

Biotechnology & Medical Research

Business Summary

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Number of employees: 5

Managers

Managers TitleAgeSince
Felix Kim FOU
 Founder - 15-03-31
Martin Lehr FOU
 Founder 40 15-03-31
Jennifer Minai-Azary DFI
 Director of Finance/CFO 46 21-10-31
Priya Marreddy CTO
 Chief Tech/Sci/R&D Officer - 22-03-31
Christopher Beck COO
 Chief Operating Officer - 22-01-04
Alex Levit LAW
 General Counsel 45 21-03-31
Evan G. Dick PRN
 Corporate Officer/Principal 72 -

Members of the board

Members of the board TitleAgeSince
Richard Berman CHM
 Chairman 81 21-02-28
Jennifer Stacey BRD
 Director/Board Member 59 21-02-28
Philip Kantoff BRD
 Director/Board Member 69 18-11-30
Linda West BRD
 Director/Board Member 64 21-02-28
Martin Lehr FOU
 Founder 40 15-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,998,312 72,912,907 ( 97.22 %) 0 97.22 %

Shareholders

NameEquities%Valuation
Avidity Partners Management LP
10.37 %
7,776,296 10.37 % 11 M $
Great Point Partners LLC
9.893 %
7,419,355 9.893 % 10 M $
Nextech Invest AG
9.893 %
7,419,355 9.893 % 10 M $
Deep Track Capital LP
9.893 %
7,419,355 9.893 % 10 M $
Opaleye Management, Inc.
1.478 %
1,108,357 1.478 % 2 M $
Martin Lehr
1.307 %
979,891 1.307 % 1 M $
Ally Bridge Group HK Ltd
0.9680 %
725,951 0.9680 % 1 M $
Vanguard Group, Inc. (Subfiler)
0.7978 %
598,303 0.7978 % 825 658 $
Affinity Asset Advisors LLC
0.4384 %
328,817 0.4384 % 453 767 $
UBS O'Connor LLC
0.3956 %
296,675 0.3956 % 409 412 $

Company contact information

Context Therapeutics, Inc.

2001 Market Street Unit 15

19103, Philadelphia

+

http://www.contexttherapeutics.com
address Context Therapeutics Inc.

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. Stock
  4. Company Context Therapeutics Inc.